UNSPSC 51151612: Hyoscyamine

This classification denotes an antimuscarinic agent with the molecular formula C17H23NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier PX44XO846X, chemically known as 1alphah,5alphah-tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate but more generally known as hyoscyamine, which bears U.S. National Institutes of Health Compound Identifier 3661. European Medicines Agency schedules Hyoscyamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14160MIG.

World Health Organization schedules hyoscyamine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.

UNSPSC 51151612 Hyoscyamine, a Commodity code, sees minimal recent state and local activity directly aligned with its nominal scope. The two recent opportunities tagged to this code involve naloxone procurement and pharmacy benefit management programs—neither of which represent hyoscyamine, an anticholinergic medication used primarily in gastrointestinal and urinary antispasmodic applications. The mismatch between the code's therapeutic category and the actual work being solicited suggests that state and local procurement offices may be using this code inconsistently or that the tagging reflects a broader pharmaceutical-acquisition category rather than hyoscyamine-specific demand. Issuing bodies in the available record include a county health department (Seminole County, Florida) and a state health and human services commission (Texas HHS), indicating that pharmaceutical procurement at the state and local level can span county-level community health initiatives and statewide pharmacy benefit programs.

The two identifiable recent opportunities show activity in Florida and Texas. Seminole County, Florida released an IFB (Solicitation IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023—though the posted date and due date are inconsistent in the source. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs without a formal competitive timeline. Neither opportunity directly procures hyoscyamine. The code shows insufficient recent activity to support a pursue decision; vendors should monitor whether future state and local pharmaceutical solicitations are tagged to this code more accurately, and consider whether the category may be used as a catch-all for multiline pharmaceutical purchases.